Phase 1 Osteoporosis Trial, Recruiting NCT07365514 Sponsor: University of Connecticut Condition: Osteoporosis
Back to Osteoporosis

Phase 1 Osteoporosis Trial, Recruiting

NCT07365514
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 45 to 70 years who have gone through menopause, with their last menstrual period no more than 10 years ago
  • People who have not used hormone replacement therapy for at least one year before the study begins
  • People who currently exercise less than 7 hours per week and are willing to avoid exercise for 24 hours before each blood and stool sample is collected
  • People who are willing to take a blackcurrant dietary supplement or a placebo capsule (up to 3 capsules per day, 392mg each)
  • People who are willing to stop taking any other dietary supplements for the entire duration of the study
  • People who are willing to avoid foods very high in anthocyanins (a type of natural pigment found in dark berries) and fermented dairy products containing certain live bacteria (such as some yoghurts or probiotic products)
  • People who are willing to have three blood draws, three stool samples collected, and three bone scans during the study

Who may not be able to join:

  • People with a history of heart or cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes, arthritis, or other long-term inflammatory conditions
  • People who currently smoke
  • People taking prescription medications known to affect bone strength or calcium levels in the body
  • People who have taken bone-building agents such as parathyroid hormone, growth hormone, or steroids within 3 months before the study starts
  • People taking medications that affect bleeding (such as blood thinners) or people who have a bleeding disorder
  • People who drink more than 2 alcoholic drinks per day, or more than 12 drinks per week
  • People who have surgery planned during the study period or within 2 weeks after the study ends
  • People with a known sensitivity or allergy to rice powder (used in the placebo capsules)
  • People who have a medical procedure planned that involves iodine, barium, or nuclear medicine during the study period
  • Students or employees of UConn who are taught by, or report directly to, any of the key study staff
  • People who are key study personnel themselves, or who are partners, dependents, or close relatives of key study personnel

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ock Chun, PhD, University of Connecticut

Phone: 860-486-6275

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
University of Connecticut
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Bone Mineral Density (BMD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov